Sign in
PROK Stock Price, Chart, Stats & News
ProKidney Corp.
Save
615.34M
Market cap
–
Current P/E
–
Forward P/E
PROK chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -218.81% |
Operating margin | -18477.83% |
Pretax margin | -16931.47% |
Net margin | -7725.20% |
Effective tax rate | -0.27% |
ROA | -20.56% |
ROE | 6.86% |
D/E | -0.00x |
Interest coverage ratio | -41251.75x |
PROK valuation
P/E | – |
P/S | 518.73x |
P/B | -0.21x |
P/CF | -1.80x |
P/FCF | -3.42x |
P/OCF | -1.80x |
PEG | -0.57x |
EV multiple | -3.84x |
About
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease.
Similar securities
Based on sector and market capitalization
Report issue